18 March 2021 - Kisqali is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners and the broadest spectrum of patients in two Phase III trials in advanced breast cancer.
Novartis is pleased to announce that statistically significant overall survival results for Kisqali (ribociclib) in combination therapy have been approved within the Kisqali Product Monograph.